Beomsu Shin1, Won-Jung Koh1, Byeong-Ho Jeong1, Hongseok Yoo1, Hye Yun Park1, Gee Young Suh2, O Jung Kwon1, Kyeongman Jeon3. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: kjeon@skku.edu.
Abstract
BACKGROUND: A serum galactomannan (GM) antigen test has been widely used to diagnose invasive pulmonary aspergillosis. However, there are limited data on the use of the serum GM antigen test for the serologic diagnosis of chronic pulmonary aspergillosis (CPA). METHODS: Data were collected from all consecutive patients with a clinical suspicion of CPA who underwent a serum GM antigen test. RESULTS: In total, 334 patients who were suspected to have CPA were eligible for this study and 168 (50%) patients were finally diagnosed with CPA. The serum GM antigen test was positive in 38 (23%) patients with CPA and in 25 (15%) patients without CPA. The sensitivity of the serum GM antigen test was 23% (95% confidence interval [CI], 17-30%), and its specificity was 85% (95% CI, 79-90%), with positive and negative predictive values of 60% (95% CI, 47-72%) and 52% (95% CI, 46-58%), respectively. The accuracy of the test was 54%. The area under the receiver operating characteristic curve was 0.538 (95% CI, 0.496-0.580). CONCLUSION: The serum GM antigen test could not be used for the serologic diagnosis of CPA.
BACKGROUND: A serum galactomannan (GM) antigen test has been widely used to diagnose invasive pulmonary aspergillosis. However, there are limited data on the use of the serum GM antigen test for the serologic diagnosis of chronic pulmonary aspergillosis (CPA). METHODS: Data were collected from all consecutive patients with a clinical suspicion of CPA who underwent a serum GM antigen test. RESULTS: In total, 334 patients who were suspected to have CPA were eligible for this study and 168 (50%) patients were finally diagnosed with CPA. The serum GM antigen test was positive in 38 (23%) patients with CPA and in 25 (15%) patients without CPA. The sensitivity of the serum GM antigen test was 23% (95% confidence interval [CI], 17-30%), and its specificity was 85% (95% CI, 79-90%), with positive and negative predictive values of 60% (95% CI, 47-72%) and 52% (95% CI, 46-58%), respectively. The accuracy of the test was 54%. The area under the receiver operating characteristic curve was 0.538 (95% CI, 0.496-0.580). CONCLUSION: The serum GM antigen test could not be used for the serologic diagnosis of CPA.
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079
Authors: David W Denning; Iain D Page; Jeremiah Chakaya; Kauser Jabeen; Cecilia M Jude; Muriel Cornet; Ana Alastruey-Izquierdo; Felix Bongomin; Paul Bowyer; Arunaloke Chakrabarti; Sara Gago; John Guto; Bruno Hochhegger; Martin Hoenigl; Muhammad Irfan; Nicholas Irurhe; Koichi Izumikawa; Bruce Kirenga; Veronica Manduku; Samihah Moazam; Rita O Oladele; Malcolm D Richardson; Juan Luis Rodriguez Tudela; Anna Rozaliyani; Helmut J F Salzer; Richard Sawyer; Nasilele F Simukulwa; Alena Skrahina; Charlotte Sriruttan; Findra Setianingrum; Bayu A P Wilopo; Donald C Cole; Haileyesus Getahun Journal: Emerg Infect Dis Date: 2018-08 Impact factor: 6.883